Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22443262 | 1.00 | KDM4E (0.40) | KDM4EPOLBLMNAGAANPC1 | |
| SCHEMBL21840253 | 0.95 | KDM4E (0.39) | KDM4EPOLBLMNAGAANPC1 | |
| SCHEMBL21840252 | 0.95 | KDM4E (0.39) | KDM4EPOLBLMNAGAANPC1 | |
| SCHEMBL29687429 | 0.95 | KDM4E (0.39) | KDM4EPOLBLMNAGAANPC1 | |
| SCHEMBL20527162 | 0.94 | KDM4E (0.38) | KDM4EPOLBLMNAGAANPC1 | |
| SCHEMBL30887615 | 0.94 | KDM4E (0.38) | KDM4EPOLBLMNAGAANPC1 | |
| SCHEMBL20527164 | 0.94 | KDM4E (0.38) | KDM4EPOLBLMNAGAANPC1 | |
| SCHEMBL29424505 | 0.93 | KDM4E (0.37) | KDM4EPOLBLMNAGAANPC1 | |
| SCHEMBL29424517 | 0.90 | KDM4E (0.37) | KDM4EPOLBLMNAGAANPC1 | |
| SCHEMBL29424452 | 0.90 | KDM4E (0.37) | KDM4EPOLBLMNAGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209099-B2 | Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer | MEDIMMUNE LIMITED (GB) | 2025-01-28 | — | — | US | disclosed |
| EP-3938372-B1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MEDIMMUNE LTD (GB) | 2023-10-25 | — | — | EP | disclosed |
| US-20220160881-A1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MEDIMMUNE LIMITED (GB) | 2022-05-26 | — | — | US | disclosed |
| EP-3938372-A1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MedImmune Limited (GB) | 2022-01-19 | — | — | EP | disclosed |
| WO-2020187721-A1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MEDIMMUNE LIMITED (GB) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160881-A1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | BCR, UGT2B17, BCL6B | KDM4E 646/4885POLB 2671/4885LMNA 3174/4885 |
| US-12209099-B2 | Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer | BCR, UGT2B17, BCL6B | KDM4E 646/4885POLB 2671/4885LMNA 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.